Barinthus Biotherapeutics PLC Sponsored ADR (BRNS)
(Delayed Data from NSDQ)
$1.31 USD
-0.07 (-5.07%)
Updated Aug 6, 2025 03:55 PM ET
After-Market: $1.36 +0.05 (3.82%) 7:24 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BRNS 1.31 -0.07(-5.07%)
Will BRNS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BRNS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BRNS
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Strong Buy: Here's Why
BRNS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BRNS
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
US Stocks Mixed; Bank of America Earnings Top Views
Barinthus Biotherapeutics Approves Key Proposals at AGM
Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June ...